139 related articles for article (PubMed ID: 15357956)
1. Discovery of potent and orally bioavailable N,N'-diarylurea antagonists for the CXCR2 chemokine receptor.
Jin Q; Nie H; McCleland BW; Widdowson KL; Palovich MR; Elliott JD; Goodman RM; Burman M; Sarau HM; Ward KW; Nord M; Orr BM; Gorycki PD; Busch-Petersen J
Bioorg Med Chem Lett; 2004 Sep; 14(17):4375-8. PubMed ID: 15357956
[TBL] [Abstract][Full Text] [Related]
2. Carboxylic acid bioisosteres acylsulfonamides, acylsulfamides, and sulfonylureas as novel antagonists of the CXCR2 receptor.
Winters MP; Crysler C; Subasinghe N; Ryan D; Leong L; Zhao S; Donatelli R; Yurkow E; Mazzulla M; Boczon L; Manthey CL; Molloy C; Raymond H; Murray L; McAlonan L; Tomczuk B
Bioorg Med Chem Lett; 2008 Mar; 18(6):1926-30. PubMed ID: 18308567
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist.
Dwyer MP; Yu Y; Chao J; Aki C; Chao J; Biju P; Girijavallabhan V; Rindgen D; Bond R; Mayer-Ezel R; Jakway J; Hipkin RW; Fossetta J; Gonsiorek W; Bian H; Fan X; Terminelli C; Fine J; Lundell D; Merritt JR; Rokosz LL; Kaiser B; Li G; Wang W; Stauffer T; Ozgur L; Baldwin J; Taveras AG
J Med Chem; 2006 Dec; 49(26):7603-6. PubMed ID: 17181143
[TBL] [Abstract][Full Text] [Related]
4. Hit-to-Lead studies: the discovery of potent, orally bioavailable thiazolopyrimidine CXCR2 receptor antagonists.
Baxter A; Cooper A; Kinchin E; Moakes K; Unitt J; Wallace A
Bioorg Med Chem Lett; 2006 Feb; 16(4):960-3. PubMed ID: 16297626
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and structure-activity relationships of new disubstituted phenyl-containing 3,4-diamino-3-cyclobutene-1,2-diones as CXCR2 receptor antagonists.
Lai G; Merritt JR; He Z; Feng D; Chao J; Czarniecki MF; Rokosz LL; Stauffer TM; Rindgen D; Taveras AG
Bioorg Med Chem Lett; 2008 Mar; 18(6):1864-8. PubMed ID: 18304809
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and structure-activity relationships of 3,4-diaminocyclobut-3-ene-1,2-dione CXCR2 antagonists.
Merritt JR; Rokosz LL; Nelson KH; Kaiser B; Wang W; Stauffer TM; Ozgur LE; Schilling A; Li G; Baldwin JJ; Taveras AG; Dwyer MP; Chao J
Bioorg Med Chem Lett; 2006 Aug; 16(15):4107-10. PubMed ID: 16697193
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor.
Widdowson KL; Elliott JD; Veber DF; Nie H; Rutledge MC; McCleland BW; Xiang JN; Jurewicz AJ; Hertzberg RP; Foley JJ; Griswold DE; Martin L; Lee JM; White JR; Sarau HM
J Med Chem; 2004 Mar; 47(6):1319-21. PubMed ID: 14998320
[TBL] [Abstract][Full Text] [Related]
8. Fluoroalkyl alpha side chain containing 3,4-diamino-cyclobutenediones as potent and orally bioavailable CXCR2-CXCR1 dual antagonists.
Biju P; Taveras AG; Dwyer MP; Yu Y; Chao J; Hipkin RW; Fan X; Rindgen D; Fine J; Lundell D
Bioorg Med Chem Lett; 2009 Mar; 19(5):1431-3. PubMed ID: 19196511
[TBL] [Abstract][Full Text] [Related]
9. Comparison of N,N'-diarylsquaramides and N,N'-diarylureas as antagonists of the CXCR2 chemokine receptor.
McCleland BW; Davis RS; Palovich MR; Widdowson KL; Werner ML; Burman M; Foley JJ; Schmidt DB; Sarau HM; Rogers M; Salyers KL; Gorycki PD; Roethke TJ; Stelman GJ; Azzarano LM; Ward KW; Busch-Petersen J
Bioorg Med Chem Lett; 2007 Mar; 17(6):1713-7. PubMed ID: 17236763
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and evaluation of novel 3-amino-4-hydrazine-cyclobut-3-ene-1,2-diones as potent and selective CXCR2 chemokine receptor antagonists.
Liu S; Liu Y; Wang H; Ding Y; Wu H; Dong J; Wong A; Chen SH; Li G; Chan M; Sawyer N; Gervais FG; Henault M; Kargman S; Bedard LL; Han Y; Friesen R; Lobell RB; Stout DM
Bioorg Med Chem Lett; 2009 Oct; 19(19):5741-5. PubMed ID: 19713110
[TBL] [Abstract][Full Text] [Related]
11. C(4)-alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists.
Chao J; Taveras AG; Chao J; Aki C; Dwyer M; Yu Y; Purakkattle B; Rindgen D; Jakway J; Hipkin W; Fosetta J; Fan X; Lundell D; Fine J; Minnicozzi M; Phillips J; Merritt JR
Bioorg Med Chem Lett; 2007 Jul; 17(13):3778-83. PubMed ID: 17459706
[TBL] [Abstract][Full Text] [Related]
12. Diaminocyclobutenediones as potent and orally bioavailable CXCR2 receptor antagonists: SAR in the phenolic amide region.
Aki C; Chao J; Ferreira JA; Dwyer MP; Yu Y; Chao J; Merritt RJ; Lai G; Wu M; Hipkin RW; Fan X; Gonsiorek W; Fosseta J; Rindgen D; Fine J; Lundell D; Taveras AG; Biju P
Bioorg Med Chem Lett; 2009 Aug; 19(15):4446-9. PubMed ID: 19525110
[TBL] [Abstract][Full Text] [Related]
13. N,N'-Diarylcyanoguanidines as antagonists of the CXCR2 and CXCR1 chemokine receptors.
Nie H; Widdowson KL; Palovich MR; Fu W; Elliott JD; Bryan DL; Burman M; Schmidt DB; Foley JJ; Sarau HM; Busch-Petersen J
Bioorg Med Chem Lett; 2006 Nov; 16(21):5513-6. PubMed ID: 16934456
[TBL] [Abstract][Full Text] [Related]
14. Imidazolylpyrimidine based CXCR2 chemokine receptor antagonists.
Ho KK; Auld DS; Bohnstedt AC; Conti P; Dokter W; Erickson S; Feng D; Inglese J; Kingsbury C; Kultgen SG; Liu RQ; Masterson CM; Ohlmeyer M; Rong Y; Rooseboom M; Roughton A; Samama P; Smit MJ; Son E; van der Louw J; Vogel G; Webb M; Wijkmans J; You M
Bioorg Med Chem Lett; 2006 May; 16(10):2724-8. PubMed ID: 16540318
[TBL] [Abstract][Full Text] [Related]
15. 3,4-Diamino-1,2,5-thiadiazole as potent and selective CXCR2 antagonists.
Biju P; Taveras AG; Yu Y; Zheng J; Hipkin RW; Fossetta J; Fan X; Fine J; Lundell D
Bioorg Med Chem Lett; 2009 Mar; 19(5):1434-7. PubMed ID: 19200721
[TBL] [Abstract][Full Text] [Related]
16. Nonpeptidergic allosteric antagonists differentially bind to the CXCR2 chemokine receptor.
de Kruijf P; van Heteren J; Lim HD; Conti PG; van der Lee MM; Bosch L; Ho KK; Auld D; Ohlmeyer M; Smit MJ; Wijkmans JC; Zaman GJ; Smit MJ; Leurs R
J Pharmacol Exp Ther; 2009 May; 329(2):783-90. PubMed ID: 19190236
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist.
Gonsiorek W; Fan X; Hesk D; Fossetta J; Qiu H; Jakway J; Billah M; Dwyer M; Chao J; Deno G; Taveras A; Lundell DJ; Hipkin RW
J Pharmacol Exp Ther; 2007 Aug; 322(2):477-85. PubMed ID: 17496166
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and structure-activity relationships of heteroaryl substituted-3,4-diamino-3-cyclobut-3-ene-1,2-dione CXCR2/CXCR1 receptor antagonists.
Yu Y; Dwyer MP; Chao J; Aki C; Chao J; Purakkattle B; Rindgen D; Bond R; Mayer-Ezel R; Jakway J; Qiu H; Hipkin RW; Fossetta J; Gonsiorek W; Bian H; Fan X; Terminelli C; Fine J; Lundell D; Merritt JR; He Z; Lai G; Wu M; Taveras A
Bioorg Med Chem Lett; 2008 Feb; 18(4):1318-22. PubMed ID: 18242983
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationship studies of novel 3-oxazolidinedione-6-naphthyl-2-pyridinones as potent and orally bioavailable EP3 receptor antagonists.
Morales-Ramos ÁI; Li YH; Hilfiker M; Mecom JS; Eidam P; Shi D; Tseng PS; Brooks C; Zhang D; Wang N; Jaworski JP; Morrow D; Fries H; Edwards R; Jin J
Bioorg Med Chem Lett; 2011 May; 21(10):2806-11. PubMed ID: 21514150
[TBL] [Abstract][Full Text] [Related]
20. 3,4-Diamino-2,5-thiadiazole-1-oxides as potent CXCR2/CXCR1 antagonists.
Biju P; Taveras A; Yu Y; Zheng J; Chao J; Rindgen D; Jakway J; Hipkin RW; Fossetta J; Fan X; Fine J; Qiu H; Merritt JR; Baldwin JJ
Bioorg Med Chem Lett; 2008 Jan; 18(1):228-31. PubMed ID: 18006311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
